Elite, a specialty pharmaceutical company, is introducing its generic Adderall XR via its marketing partner Lannett.
Adderall XR is a once-daily central nervous system stimulant and is indicated for the treatment of attention deficit hyperactivity hisorder.
The product, which is a generic of Shire's Adderall XR, is an extended-release mixed salt of a single-entity amphetamine product (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, amphetamine sulfate). The capsules are available in dosage strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg.
"Generic Adderall XR extends our offering of treatments for ADHD," said Lannett CEO Tim Crew. "As we have previously noted, while the market for Adderall XR is sizable, there currently are several generic suppliers for this product. Our entire team continues to work diligently to bring more affordable medicines to patients."
Adderall XR, including generic versions, have a market value of approximately $1.3 billion for the 12 months ended January 2020, according to IQVIA.
This generic Adderall XR product is jointly owned by Elite and SunGen Pharma and is the second product launched from their collaboration. Elite will manufacture and package the generic product on a cost-plus basis. Lannett will be the exclusive U.S. distributor for the product and will provide sales, marketing, and distribution.